๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

CLINICAL DEVELOPMENT OF HISTONE DEACETYLASE INHIBITORS AS ANTICANCER AGENTS*

โœ Scribed by Drummond, Daryl C.; Noble, Charles O.; Kirpotin, Dmitri B.; Guo, Zexiong; Scott, Gary K.; Benz, Christopher C.

Book ID
118037084
Publisher
Annual Reviews
Year
2005
Tongue
English
Weight
517 KB
Volume
45
Category
Article
ISSN
0362-1642

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Dietary agents as histone deacetylase in
Dietary agents as histone deacetylase inhibitors
โœ Melinda C. Myzak; Emily Ho; Roderick H. Dashwood ๐Ÿ“‚ Article ๐Ÿ“… 2006 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 109 KB

## Abstract In cancer cells, an imbalance often exists between histone acetyltransferase (HAT) and histone deacetylase (HDAC) activities, and various drug companies are actively seeking competitive HDAC inhibitors for chemotherapeutic intervention. Cancer cells appear to be more sensitive than nont

Histone deacetylase inhibitors: Understa
Histone deacetylase inhibitors: Understanding a new wave of anticancer agents
โœ Ana Villar-Garea; Manel Esteller ๐Ÿ“‚ Article ๐Ÿ“… 2004 ๐Ÿ› John Wiley and Sons ๐ŸŒ French โš– 346 KB

## Abstract Cancer is as much an epigenetic disease as it is a genetic and cytogenetic disease. The discovery that drastic changes in DNA methylation and histone modifications are commonly found in human tumors has inspired various laboratories and pharmaceutical companies to develop and study epig